Hepatology international · 2026
New therapies for primary biliary cholangitis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sohal Aalam, Alamgir Mariam, Kowdley Kris V
Аннотация
BACKGROUND: Primary Biliary Cholangitis (PBC) is a cholestatic autoimmune liver disease of small bile ducts. Ursodeoxycholic acid (UDCA) was approved as a first line therapeutic option for PBC in 1997. It was later noted that 40% of patients with PBC are either non-responders or intolerant to UDCA. In 2016, obeticholic acid (OCA) was approved as a second-line therapy for PBC. However, due to the side effects associated with OCA and the FDA restricting its use in patients with cirrhosis, there was a need for additional therapies.
AIMS: This review summarizes the current literature regarding the new and emerging therapies for patients with PBC.
KEY FINDINGS: In 2024, two new therapies, elafibranor and seladelpar were approved as a second-line treatment for PBC. In 2025 OCA was withdrawn from the market. Multiple additional therapies targeting biochemical remission are under investigation. Furthermore, a new class of medication, ileal bile acid transporter inhibitors (IBAT inhibitors), is being studied for pruritus among these patients.
CONCLUSION: The therapeutic landscape for PBC has been rapidly evolving with the discovery of second-line agents. Ongoing trials studying biochemical response, symptom control and long-term clinical outcomes among patients with PBC will be beneficial.
AIMS: This review summarizes the current literature regarding the new and emerging therapies for patients with PBC.
KEY FINDINGS: In 2024, two new therapies, elafibranor and seladelpar were approved as a second-line treatment for PBC. In 2025 OCA was withdrawn from the market. Multiple additional therapies targeting biochemical remission are under investigation. Furthermore, a new class of medication, ileal bile acid transporter inhibitors (IBAT inhibitors), is being studied for pruritus among these patients.
CONCLUSION: The therapeutic landscape for PBC has been rapidly evolving with the discovery of second-line agents. Ongoing trials studying biochemical response, symptom control and long-term clinical outcomes among patients with PBC will be beneficial.